Reduced Healthcare Costs Among Clobazam-Treated Patients With Lennox–Gastaut Syndrome (P6.287)

Objective: To compare healthcare costs in patients with probable Lennox–Gastaut syndrome (LGS) before and after clobazam (CLB) initiation and to evaluate the impact of CLB availability on healthcare costs regardless of CLB use. Background: A previously reported method did not control for increasing cost trends prior to treatment initiation, possibly underestimating the overall budget impact of CLB initiation. Design/Methods: In Studies 1 and 2, annual costs in probable LGS patients were compared during the year before and after CLB initiation; Study 2 was conducted as a time-series analysis of monthly costs after CLB initiation. In Study 3, average costs per patient per month (PPPM) were compared before and after the commercial availability of CLB in all probable LGS patients, regardless of CLB use. Results: Annual epilepsy-related medical costs significantly decreased post-CLB initiation in Study 1 ($23,740 vs $19,958, P =0.004), and slightly decreased in Study 2 ($18,204 vs $14,466, P =0.216). When increasing pre-CLB costs were controlled, reductions of $1,539 and $2,236 in all-cause and epilepsy-related annual medical costs were noted. In Study 3, there was a significant decrease in PPPM all-cause total costs following the commercial availability of CLB regardless of CLB use ($3,752 vs $2,879, P P P Conclusions: Increased annual costs in LGS patients post-CLB were found in studies 1 and 2 where increasing costs pre-CLB were not considered. In the time-series analysis controlling for increasing costs pre-CLB, there were cost reductions following CLB initiation. Additionally, decreased costs following CLB availability occurred regardless of CLB use. Alternative methodologies such as those used in Studies 2 and 3 may be less susceptible to underestimating the cost benefits of CLB introduction in the LGS population. Study Supported by: Lundbeck Disclosure: Dr. Stern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Eisai, Sunovion, Lundbeck, and Cyberonics. Dr. Ogbonnaya has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Xcenda, LLC, Scientific Consulting employee. Dr. Tuttle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Analysis Group, Inc employee. Dr. Cheng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Analysis Group, Inc employee. Dr. Montouris has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EISAI,LUNDBECK, SK LIFE, UCB PHARMA FOR EXPERT PANEL ON PREGNANCY ,ACCORDA THERAPEUTICS. Dr. Pina-Garza has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion, UCB Pharma, Supernus, Lundbeck, Eisai. Dr. Kymes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employment/Ownership Interest: Lundbeck; CVS Health: Ownership Interest. Dr. Kymes holds stock and/or stock options in Stock in Lundbeck that is greater than $10,000 in value, which sponsored research in which Dr. Kymes was involved as an investigator. Dr. Lokhandwala has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Xcenda, LLC, Scientific Consulting employee. Dr. Vekeman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Groupe d’analyse, Ltee employee. Dr. Francois has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck LLC employee.